DOCSLIB.ORG

13.122.936 1 BILL ANALYSIS C.S.H.B. 1333 By: Perry Criminal Jurisprudence Committee Report (Substituted) BACKGROUND and PURPOSE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
13.122.936 1 BILL ANALYSIS C.S.H.B. 1333 By: Perry Criminal Jurisprudence Committee Report (Substituted) BACKGROUND and PURPOSE BILL ANALYSIS C.S.H.B. 1333 By: Perry Criminal Jurisprudence Committee Report (Substituted) BACKGROUND AND PURPOSE Interested parties report that some synthetic drugs are currently being marketed as bath salts and incense, when these products actually contain chemical compounds that mimic the effects of illegal controlled substances. These synthetic drugs have dangerous and deadly consequences, such as hallucination, severe agitation, elevated heart rate and blood pressure, chest pains, tremors, seizures, and, in some cases, death, and are being sold at the retail level to Texans of all ages. Despite current laws that address the sale, manufacture, and possession of synthetic drugs, the ease with which these chemical compounds can be changed while still producing similar effects creates difficulties in enforcing the laws. C.S.H.B. 1333 seeks to address this issue by amending provisions of the Texas Controlled Substances Act. RULEMAKING AUTHORITY It is the committee's opinion that this bill does not expressly grant any additional rulemaking authority to a state officer, department, agency, or institution. ANALYSIS C.S.H.B. 1333 amends the Health and Safety Code to clarify that the definition of "controlled substance" includes a substance listed in Penalty Group 2-A of the Texas Controlled Substances Act and to expand the definition of "controlled substance analogue" to include a substance with a chemical structure substantially similar to the chemical structure of a controlled substance in Penalty Group 2-A and a substance specifically designed to produce an effect substantially similar to, or greater than, the effect of a controlled substance in Penalty Group 2-A. C.S.H.B. 1333 expands the list of substances in Penalty Group 2 of the Texas Controlled Substances Act to include any quantity of certain specified chemical designations of hallucinogenic substances and, if applicable, their salts, isomers, and salts of isomers; a material, compound, mixture, or preparation containing any quantity of Etaqualone and its salts; the compound Methedrone and certain other compounds that are structurally derived from 2- aminopropanal by substitution at the 1-position with any monocyclic or fused-polycyclic ring system and that are further modified by certain specified substitutions. The bill expands the list of substances in Penalty Group 2-A to include any quantity of certain specified synthetic chemical compounds that are cannabinoid receptor agonists and that mimic the pharmacological effect of naturally occurring cannabinoids. C.S.H.B. 1333 includes Penalty Group 2-A among the penalty groups that, for the purposes of the prosecution of an offense under the Texas Controlled Substances Act involving the manufacture, delivery, or possession of a controlled substance, include a controlled substance analogue that has a chemical structure substantially similar to the chemical structure of a controlled substance listed in the applicable penalty group or is specifically designed to produce an effect substantially similar to, or greater than, a controlled substance in the applicable penalty group. 13.122.936 83R 26875 Substitute Document Number: 83R 13830 1 EFFECTIVE DATE September 1, 2013. COMPARISON OF ORIGINAL AND SUBSTITUTE While C.S.H.B. 1333 may differ from the original in minor or nonsubstantive ways, the following comparison is organized and highlighted in a manner that indicates the substantial differences between the introduced and committee substitute versions of the bill. INTRODUCED HOUSE COMMITTEE SUBSTITUTE SECTION 1. Section 481.002(6), Health SECTION 1. Sections 481.002(5) and (6), and Safety Code, is amended to read as Health and Safety Code, are amended to follows: read as follows: No equivalent provision. (5) "Controlled substance" means a substance, including a drug, an adulterant, and a dilutant, listed in Schedules I through V or Penalty Group [Groups] 1, 1-A, [or] 2, 2-A, 3, or [through] 4. The term includes the aggregate weight of any mixture, solution, or other substance containing a controlled substance. (6) "Controlled substance analogue" means: (6) "Controlled substance analogue" means: (A) a substance with a chemical structure (A) a substance with a chemical structure substantially similar to the chemical substantially similar to the chemical structure of a controlled substance in structure of a controlled substance in Schedule I or II or Penalty Group 1, 1-A, Schedule I or II or Penalty Group 1, 1-A, [or] 2, or 2-A; or [or] 2, or 2-A; or (B) a substance specifically designed to (B) a substance specifically designed to produce an effect substantially similar to, or produce an effect substantially similar to, or greater than, the effect of a controlled greater than, the effect of a controlled substance in Schedule I or II or Penalty substance in Schedule I or II or Penalty Group 1, 1-A, [or] 2, or 2-A. Group 1, 1-A, [or] 2, or 2-A. SECTION 2. Section 481.103(a), Health SECTION 2. Section 481.103(a), Health and Safety Code, is amended to read as and Safety Code, is amended to read as follows: follows: (a) Penalty Group 2 consists of: (a) Penalty Group 2 consists of: (1) any quantity of the following (1) any quantity of the following hallucinogenic substances, their salts, hallucinogenic substances, their salts, isomers, and salts of isomers, unless isomers, and salts of isomers, unless specifically excepted, if the existence of specifically excepted, if the existence of these salts, isomers, and salts of isomers is these salts, isomers, and salts of isomers is possible within the specific chemical possible within the specific chemical designation: designation: alpha-ethyltryptamine; alpha-ethyltryptamine; alpha-methyltryptamine; alpha-methyltryptamine; 5-(2-aminopropyl)benzofuran (5-APB); 5-(2-aminopropyl)benzofuran (5-APB); 6-(2-aminopropyl)benzofuran (6-APB); 6-(2-aminopropyl)benzofuran (6-APB); 5-(2-aminopropyl)-2,3-dihydrobenzofuran 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-APDB); (5-APDB); 6-(2-aminopropyl)-2,3-dihydrobenzofuran 6-(2-aminopropyl)-2,3-dihydrobenzofuran 13.122.936 83R 26875 Substitute Document Number: 83R 13830 2 (6-APDB); (6-APDB); 5-(2-aminopropyl)indole (Trade or other names: 5-IT, 5-API); 6-(2-aminopropyl)indole (Trade or other names: 6-IT, 6-API); Benzothiophenylcyclohexylpiperidine Benzothiophenylcyclohexylpiperidine (BTCP); (BTCP); 4-bromo-2, 5-dimethoxyamphetamine 4-bromo-2, 5-dimethoxyamphetamine (some trade or other names: 4-bromo-2, 5- (some trade or other names: 4-bromo-2, 5- dimethoxy-alpha-methylphenethylamine; 4- dimethoxy-alpha-methylphenethylamine; 4- bromo-2, 5-DMA); bromo-2, 5-DMA); 4-bromo-2, 5-dimethoxyphenethylamine; 4-bromo-2, 5-dimethoxyphenethylamine; [1-(5-bromopentylindol-3-yl)]-(2,2,3,3- tetramethylcyclopropyl)methanone (5- bromopentyl-UR-144); 8-bromo-alpha-methyl-benzo[1,2-b:4,5- b']difuran- 4-ethanamine (Trade or other name: Bromo-DragonFLY); Bufotenine (some trade and other names: 3- Bufotenine (some trade and other names: 3- (beta- Dimethylaminoethyl)-5- (beta- Dimethylaminoethyl)-5- hydroxyindole; 3-(2-dimethylaminoethyl)- hydroxyindole; 3-(2-dimethylaminoethyl)- 5- indolol; N, N-dimethylserotonin; 5- 5- indolol; N, N-dimethylserotonin; 5- hydroxy-N, N- dimethyltryptamine; hydroxy-N, N- dimethyltryptamine; mappine); mappine); [1-(5-chloropentylindol-3-yl)]-(2,2,3,3- tetramethylcyclopropyl)methanone (5- chloropentyl-UR-144); Desoxypipradrol (2-benzhydrylpiperidine); Desoxypipradrol (2-benzhydrylpiperidine); Diethyltryptamine (some trade and other Diethyltryptamine (some trade and other names: N, N-Diethyltryptamine, DET); names: N, N-Diethyltryptamine, DET); 2, 5-dimethoxyamphetamine (some trade or 2, 5-dimethoxyamphetamine (some trade or other names: 2, 5-dimethoxy-alpha- other names: 2, 5-dimethoxy-alpha- methylphenethylamine; 2, 5-DMA); methylphenethylamine; 2, 5-DMA); 2, 5-dimethoxy-4-ethylamphetamine (trade 2, 5-dimethoxy-4-ethylamphetamine (trade or other name: DOET); or other name: DOET); 2, 5-dimethoxy-4-(n)- 2, 5-dimethoxy-4-(n)- propylthiophenethylamine (trade or other propylthiophenethylamine (trade or other name: 2C-T-7); name: 2C-T-7); Dimethyltryptamine (trade or other name: Dimethyltryptamine (trade or other name: DMT); DMT); Diphenylprolinol (diphenyl(pyrrolidin-2-yl) Diphenylprolinol (diphenyl(pyrrolidin-2-yl) methanol, D2PM); methanol, D2PM); Dronabinol (synthetic) in sesame oil and Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration U.S. Food and Drug Administration approved drug product (some trade or other approved drug product (some trade or other names for Dronabinol: (a6aR-trans)- names for Dronabinol: (a6aR-trans)- 6a,7,8,10a-tetrahydro- 6,6, 9- trimethyl-3- 6a,7,8,10a-tetrahydro- 6,6, 9- trimethyl-3- pentyl-6H- dibenzo [b,d]pyran-1-ol or (-)- pentyl-6H- dibenzo [b,d]pyran-1-ol or (-)- delta-9- (trans)- tetrahydrocannabinol); delta-9- (trans)- tetrahydrocannabinol); Ethylamine Analog of Phencyclidine (some Ethylamine Analog of Phencyclidine (some trade or other names: N-ethyl-1- trade or other names: N-ethyl-1- phenylcyclohexylamine, (1- phenylcyclohexylamine, (1- phenylcyclohexyl) ethylamine, N-(1- phenylcyclohexyl) ethylamine, N-(1- phenylcyclohexyl) ethylamine, phenylcyclohexyl) ethylamine, 13.122.936 83R 26875 Substitute Document Number: 83R 13830 3 cyclohexamine, PCE); cyclohexamine, PCE); 2-ethylamino-2-(3- 2-ethylamino-2-(3- methoxyphenyl)cyclohexanone methoxyphenyl)cyclohexanone (Trade or (methoxetamine); other name:
Load more

Recommended publications
  • Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd
    Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr.
    [Show full text]
  • Federal Register/Vol. 85, No. 167/Thursday, August 27, 2020
    Federal Register / Vol. 85, No. 167 / Thursday, August 27, 2020 / Proposed Rules 52935 BIS does not seek to expand DATES: Comments must be submitted Drug Enforcement Administration, Attn: jurisdiction over technologies that are electronically or postmarked on or DEA Federal Register Representative/ not currently subject to the EAR, such before September 28, 2020. DPW, 8701 Morrissette Drive, as ‘‘fundamental research’’ described in Interested persons may file written Springfield, Virginia 22152. § 734.8 of the EAR. comments on this proposal in FOR FURTHER INFORMATION CONTACT: BIS will review public comments accordance with 21 CFR 1308.43(g). Scott A. Brinks, Regulatory Drafting and submitted in response to this ANPRM to Commenters should be aware that the Policy Support Section, Diversion help inform BIS and its interagency electronic Federal Docket Management Control Division, Drug Enforcement partners’ efforts to identify, reevaluate System will not accept comments after Administration; Mailing Address: 8701 and subsequently control foundational 11:59 p.m. Eastern Time on the last day Morrissette Drive, Springfield, Virginia technologies. This interagency process of the comment period. 22152; Telephone: (571) 362–8209. is expected to result in rules and Interested persons may file a request SUPPLEMENTARY INFORMATION: comment periods with new control for a hearing or waiver of hearing levels for items currently controlled for pursuant to 21 CFR 1308.44 and in Posting of Public Comments AT reasons on the CCL or new ECCNs accordance with 21 CFR 1316.45 and/or Please note that all comments on the CCL for technologies currently 1316.47, as applicable. Requests for a received in response to this docket are classified as EAR99.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020
    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
    [Show full text]
  • Immediate Action New Tests and Test Updates
    Effective Date: Monday, August 26, 2013 New Tests and Test Updates Immediate Action In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, August 26, 2013 New Tests - Tests recently added to the NMS Labs test menu. New Tests are effective immediately. Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements. Discontinued Tests - Tests being discontinued with alternate testing suggestions. Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases. If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes. The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document. NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 1 of 76 Effective Date: Monday, August 26, 2013 New Tests and Test Updates Test Test Name New Test Method / Specimen Stability Scope Units Reference Discontinue
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • 124.204 Schedule I — Substances Included. 1. Schedule I Shall Consist
    1 , §124.204 124.204 Schedule I — substances included. 1. Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation: a. Acetylmethadol. b. Allylprodine. c. Alphacetylmethadol (except levo-alphacetylmethadol also known as levo-alpha- acetylmethadol, levomethadyl acetate, or LAAM). d. Alphameprodine. e. Alphamethadol. f. Alpha-Methylfentanyl (N-(1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl) propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine). g. Benzethidine. h. Betacetylmethadol. i. Betameprodine. j. Betamethadol. k. Betaprodine. l. Clonitazene. m. Dextromoramide. n. Difenoxin. o. Diampromide. p. Diethylthiambutene. q. Dimenoxadol. r. Dimepheptanol. s. Dimethylthiambutene. t. Dioxaphetyl butyrate. u. Dipipanone. v. Ethylmethylthiambutene. w. Etonitazene. x. Etoxeridine. y. Furethidine. z. Hydroxypethidine. aa. Ketobemidone. ab. Levomoramide. ac. Levophenacylmorphan. ad. Morpheridine. ae. Noracymethadol. af. Norlevorphanol. ag. Normethadone. ah. Norpipanone. ai. Phenadoxone. aj. Phenampromide. ak. Phenomorphan. al. Phenoperidine. am. Piritramide. an. Proheptazine. ao. Properidine. ap. Propiram. aq. Racemoramide. ar. Tilidine. as. Trimeperidine. at. Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-phenethyl)- 3-methyl-4-piperidinyl]-N-phenylpropanamide). Thu May 19 07:35:43 2016 Iowa Code 2016, Section 124.204 (25, 1) §124.204, 2 au. Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide). av.
    [Show full text]
  • Texas Controlled Substances Act
    HEALTH AND SAFETY CODE TITLE 6. FOOD, DRUGS, ALCOHOL, AND HAZARDOUS SUBSTANCES SUBTITLE C. SUBSTANCE ABUSE REGULATION AND CRIMES CHAPTER 481. TEXAS CONTROLLED SUBSTANCES ACT SUBCHAPTER A. GENERAL PROVISIONS Sec.A481.001.AASHORT TITLE. This chapter may be cited as the Texas Controlled Substances Act. Acts 1989, 71st Leg., ch. 678, Sec. 1, eff. Sept. 1, 1989. Sec.A481.002.AADEFINITIONS. In this chapter: (1)AA"Administer" means to directly apply a controlled substance by injection, inhalation, ingestion, or other means to the body of a patient or research subject by: (A)AAa practitioner or an agent of the practitioner in the presence of the practitioner; or (B)AAthe patient or research subject at the direction and in the presence of a practitioner. (2)AA"Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. The term does not include a common or contract carrier, public warehouseman, or employee of a carrier or warehouseman acting in the usual and lawful course of employment. (3)AA"Commissioner" means the commissioner of state health services or the commissioner 's designee. (4)AA"Controlled premises" means: (A)AAa place where original or other records or documents required under this chapter are kept or are required to be kept; or (B)AAa place, including a factory, warehouse, other establishment, or conveyance, where a person registered under this chapter may lawfully hold, manufacture, distribute, dispense, administer, possess, or otherwise dispose of a controlled substance or other item governed by the federal Controlled Substances Act (21 U.S.C.
    [Show full text]
  • MDAI (5,6Methylenedioxy2aminoindane
    human psychopharmacology Hum. Psychopharmacol Clin Exp 2013; 28: 345–355. Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/hup.2298 SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H- cyclopenta[f][1,3]benzodioxol-6-amine; ‘sparkle’; ‘mindy’) toxicity: a brief overview and update John M Corkery1,3*, Simon Elliott2, Fabrizio Schifano1,3, Ornella Corazza3 and A Hamid Ghodse1,† 1National Programme for Substance Abuse Deaths (np-SAD), International Centre for Drug Policy, St George’s, University of London, London, UK 2ROAR Forensics Ltd, Malvern, Worcestershire, UK 3School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire, UK Objectives MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; ‘sparkle’; ‘mindy’)isa psychoactive substance, sold primarily over the Internet and in ‘head’ shops as a ‘legal high’. Synthesised and used as a research chemical in the 1990s, MDAI has structural similarities to MDMA (3,4-methylenedioxy-N-methylamphetamine) and shares its behavioural properties. Recreational use of MDAI appears to have started in Europe around 2007, with a noticeable increase after 2009 in the UK and other countries. Calls to National Poisons Information Services started in 2010, although there were few presentations to emergency departments by patients complaining of undesirable physical and psychiatric effects after taking MDAI. Recreational use of this drug has been reported only occa- sionally by online user fora. There is little scientifically based literature on the pharmacological, physiological, psychopharmacological, tox- icological and epidemiological characteristics of this drug. Methods Recent literature (including ‘grey’) was searched to update what is known about MDAI, especially on its toxicity.
    [Show full text]
  • New Drugs in Europe, 2012 Europe, in Drugs New
    ISSN 1977-7841 New drugs in Europe, 2012 EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA 2012 New drugs in Europe, 2012 EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document. The contents of this publication do not necessarily reflect the official opinions of the EMCDDA’s partners, the EU Member States or any institution or agency of the European Union or European Communities. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu). Europe Direct is a service to help you find answersto your questions about the European Union. Freephone number (*): 00 800 6 7 8 9 10 11 (*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed. Cataloguing data can be found at the end of this publication. Luxembourg: Publications Office of the European Union, 2013 ISBN 978-92-9168-650-6 doi:10.2810/99367 © European Monitoring Centre for Drugs and Drug Addiction, 2013 Cais do Sodré, 1249-289 Lisbon, Portugal Tel. +351 211210200 • [email protected] • www.emcdda.europa.eu © Europol, 2013 Eisenhowerlaan 73, 2517 KK, The Hague, the Netherlands Tel.
    [Show full text]
  • Active Constituents Identification Chart (May 2010, Pre-Ban)
    Head Shop ‘Legal Highs’ Active Constituents Identification Chart (May 2010, pre-ban) •Mephedrone •Mephedrone •Mephedrone •Mephedrone •Methylone •Methylone •Methylone (66.1% as HCl salt, (82.2% as HCl salt, (14.6% as HCl salt, (39.9% as HCl salt, 54.8% as free base) 68.1% as free base ) 12.1% as free base) 33.1% as free base) •Caffeine •Benzocaine •Benzocaine •Methylone •Mephedrone •Flephedrone •Flephedrone •MDPV •Caffeine •MDPV •Lignocaine •Lignocaine •Dimethylamylamine (DMAA) •Caffeine •Caffeine Pack 1 Pack 2 •Flephedrone •MDPV •MDPV •MDPV •Butylone •Butylone •Lignocaine •Lignocaine •Lignocaine •A significant amount of what is believed •MDPV •Caffeine to be an isomer of butylone was also found. •p-Fluorophenylpiperazine •Butylone •m-Trifluoromethylphenylpiperazine •Caffeine (100 %) •Butylone •Dimethylamylamine (DMAA) (pPFP) •Caffeine (mTFMPP) •2-Phenylethylamine (2-PEA) •Caffeine •Caffeine •Hordenine •Caffeine •Methylone •m-Trifluoromethylphenylpiperazine •Mephedrone •2-Aminoindane (2-AI, •MDPV (mTFMPP) 2-indanamine) •1-MthlMethyl-4-bliibenzylpiperazine (MthlMethyl BZP) •CffiCaffeine •Caffeine •m-Trifluoromethylphenylpiperazine •Caffeine (99 %) •Butylone •Butylone (mTFMPP) •MDPV •Mephedrone •p-Fluorophenylpiperazine (pPFP) •Caffeine •Butylone •Mephedrone •2-Phenylethylamine (2-PEA) •Caffeine •Dimethylamylamine (DMAA) •Lignocaine •Dime thy lamy lam ine (DMAA) •Dime thy lamy lam ine (DMAA) •Caffeine These are the active constituents that we have found to date in the above products. It may be expected that Next Generation Compounds (NGC's)
    [Show full text]
  • AGENDA Friday, September 9, 2016 7:00 A.M
    Needham Board of Health AGENDA Friday, September 9, 2016 7:00 a.m. – 9:00 a.m. Charles River Room – Public Services Administration Building 500 Dedham Avenue, Needham MA 02492 • 7:00 to 7:05 - Welcome & Review of Minutes (July 29 & August 29) • 7:05 to 7:30 - Director and Staff Reports (July & August) • 7:30 to 7:45 - Discussion about Proposed Plastic Bag Ban Christopher Thomas, Needham Resident • 7:45 to 7:50 - Off-Street Drainage Bond Discussion & Vote • 7:50 to 8:00 - Update on Wingate Pool Variance Application * * * * * * * * * * * * * Board of Health Public Hearing • 8:00 to 8:40 - Hearing for Proposed New or Amended BOH Regulations o Body Art o Synthetic Marijuana o Drug Paraphernalia • 8:40 to 8:50 - Board Discussion of Policy Positions • Other Items (Healthy Aging, Water Quality) • Next Meeting Scheduled for Friday October 14, 2016 • Adjournment (Please note that all times are approximate) 1471 Highland Avenue, Needham, MA 02492 781-455-7500 ext 511 (tel); 781-455-0892 (fax) E-mail: [email protected] Web: www.needhamma.gov/health NEEDHAM BOARD OF HEALTH July 29, 2016 MEETING MINUTES PRESENT: Edward V. Cosgrove, PhD, Chair, Jane Fogg, Vice-Chair, M.D., and Stephen Epstein, M.D STAFF: Timothy McDonald, Director, Donna Carmichael, Catherine Delano, Maryanne Dinell, Tara Gurge GUEST: Kevin Mulkern, Aquaknot Pools, Inc., Keith Mulkern, Aquaknot Pools, Inc., David Friedman, Wingate, Paul Humphreys, Michael Tomasello, Callahan, Inc. CONVENE: 7:00 a.m. – Public Services Administration Building (PSAB), 500 Dedham Avenue, Needham MA 02492 DISCUSSION: Call To Order – 7:06 a.m. – Dr. Cosgrove, Chairman APPROVE MINUTES: Upon motion duly made and seconded, the minutes of the BOH meeting of June 17, 2016 were approved as submitted.
    [Show full text]